Global Relapsed Acute Myeloid Leukemia Drug Market 2017 - Research Report By Application, Type, Key Players, Region and Forecast to 2022

 Published Date : Mar-2018   |    Format :PDF |    Number of Pages : 113   |    Publisher : e-Market Research



 Buy Now
This report studies Relapsed Acute Myeloid Leukemia Drug in Global market, especially in North America, China, Europe, Southeast Asia, Japan and India, with production, revenue, consumption, import and export in these regions, from 2013 to 2018, and forecast to 2025.

This report focuses on top manufacturers in global market, with production, price, revenue and market share for each manufacturer, covering
    4SC AG
    AbbVie Inc.
    Actinium Pharmaceuticals, Inc.
    Agios Pharmaceuticals, Inc.
    Amgen Inc.
    Arog Pharmaceuticals, Inc.
    Array BioPharma Inc.
    Astellas Pharma Inc.
    Astex Pharmaceuticals, Inc.
    AstraZeneca Plc
    AVEO Pharmaceuticals, Inc.
    BioLineRx, Ltd.
    Boehringer Ingelheim GmbH
    Boston Biomedical, Inc.
    Bristol-Myers Squibb Company
    Calithera Biosciences, Inc.
    Celgene Corporation
    Cornerstone Pharmaceuticals, Inc.
    CTI BioPharma Corp.

On the basis of product, this report displays the production, revenue, price, market share and growth rate of each type, primarily split into
    aNK Program
    AT-9283
    BI-836858
    binimetinib
    BL-8040
    Others

By Application, the market can be split into
    Clinic
    Hospital
    Others

By Regions, this report covers (we can add the regions/countries as you want)
    North America
    China
    Europe
    Southeast Asia
    Japan
    India

If you have any special requirements, please let us know and we will offer you the report as you want.

Global Relapsed Acute Myeloid Leukemia Drug Market Professional Survey Report 2018
1 Industry Overview of Relapsed Acute Myeloid Leukemia Drug
    1.1 Definition and Specifications of Relapsed Acute Myeloid Leukemia Drug
        1.1.1 Definition of Relapsed Acute Myeloid Leukemia Drug
        1.1.2 Specifications of Relapsed Acute Myeloid Leukemia Drug
    1.2 Classification of Relapsed Acute Myeloid Leukemia Drug
        1.2.1 aNK Program
        1.2.2 AT-9283
        1.2.3 BI-836858
        1.2.4 binimetinib
        1.2.5 BL-8040
        1.2.6 Others
    1.3 Applications of Relapsed Acute Myeloid Leukemia Drug
        1.3.1 Clinic
        1.3.2 Hospital
        1.3.3 Others
    1.4 Market Segment by Regions
        1.4.1 North America
        1.4.2 China
        1.4.3 Europe
        1.4.4 Southeast Asia
        1.4.5 Japan
        1.4.6 India

2 Manufacturing Cost Structure Analysis of Relapsed Acute Myeloid Leukemia Drug
    2.1 Raw Material and Suppliers
    2.2 Manufacturing Cost Structure Analysis of Relapsed Acute Myeloid Leukemia Drug
    2.3 Manufacturing Process Analysis of Relapsed Acute Myeloid Leukemia Drug
    2.4 Industry Chain Structure of Relapsed Acute Myeloid Leukemia Drug

3 Technical Data and Manufacturing Plants Analysis of Relapsed Acute Myeloid Leukemia Drug
    3.1 Capacity and Commercial Production Date of Global Relapsed Acute Myeloid Leukemia Drug Major Manufacturers in 2017
    3.2 Manufacturing Plants Distribution of Global Relapsed Acute Myeloid Leukemia Drug Major Manufacturers in 2017
    3.3 R&D Status and Technology Source of Global Relapsed Acute Myeloid Leukemia Drug Major Manufacturers in 2017
    3.4 Raw Materials Sources Analysis of Global Relapsed Acute Myeloid Leukemia Drug Major Manufacturers in 2017

4 Global Relapsed Acute Myeloid Leukemia Drug Overall Market Overview
    4.1 2013-2018E Overall Market Analysis
    4.2 Capacity Analysis
        4.2.1 2013-2018E Global Relapsed Acute Myeloid Leukemia Drug Capacity and Growth Rate Analysis
        4.2.2 2017 Relapsed Acute Myeloid Leukemia Drug Capacity Analysis (Company Segment)
    4.3 Sales Analysis
        4.3.1 2013-2018E Global Relapsed Acute Myeloid Leukemia Drug Sales and Growth Rate Analysis
        4.3.2 2017 Relapsed Acute Myeloid Leukemia Drug Sales Analysis (Company Segment)
    4.4 Sales Price Analysis
        4.4.1 2013-2018E Global Relapsed Acute Myeloid Leukemia Drug Sales Price
        4.4.2 2017 Relapsed Acute Myeloid Leukemia Drug Sales Price Analysis (Company Segment)

5 Relapsed Acute Myeloid Leukemia Drug Regional Market Analysis
    5.1 North America Relapsed Acute Myeloid Leukemia Drug Market Analysis
        5.1.1 North America Relapsed Acute Myeloid Leukemia Drug Market Overview
        5.1.2 North America 2013-2018E Relapsed Acute Myeloid Leukemia Drug Local Supply, Import, Export, Local Consumption Analysis
        5.1.3 North America 2013-2018E Relapsed Acute Myeloid Leukemia Drug Sales Price Analysis
        5.1.4 North America 2017 Relapsed Acute Myeloid Leukemia Drug Market Share Analysis
    5.2 China Relapsed Acute Myeloid Leukemia Drug Market Analysis
        5.2.1 China Relapsed Acute Myeloid Leukemia Drug Market Overview
        5.2.2 China 2013-2018E Relapsed Acute Myeloid Leukemia Drug Local Supply, Import, Export, Local Consumption Analysis
        5.2.3 China 2013-2018E Relapsed Acute Myeloid Leukemia Drug Sales Price Analysis
        5.2.4 China 2017 Relapsed Acute Myeloid Leukemia Drug Market Share Analysis
    5.3 Europe Relapsed Acute Myeloid Leukemia Drug Market Analysis
        5.3.1 Europe Relapsed Acute Myeloid Leukemia Drug Market Overview
        5.3.2 Europe 2013-2018E Relapsed Acute Myeloid Leukemia Drug Local Supply, Import, Export, Local Consumption Analysis
        5.3.3 Europe 2013-2018E Relapsed Acute Myeloid Leukemia Drug Sales Price Analysis
        5.3.4 Europe 2017 Relapsed Acute Myeloid Leukemia Drug Market Share Analysis
    5.4 Southeast Asia Relapsed Acute Myeloid Leukemia Drug Market Analysis
        5.4.1 Southeast Asia Relapsed Acute Myeloid Leukemia Drug Market Overview
        5.4.2 Southeast Asia 2013-2018E Relapsed Acute Myeloid Leukemia Drug Local Supply, Import, Export, Local Consumption Analysis
        5.4.3 Southeast Asia 2013-2018E Relapsed Acute Myeloid Leukemia Drug Sales Price Analysis
        5.4.4 Southeast Asia 2017 Relapsed Acute Myeloid Leukemia Drug Market Share Analysis
    5.5 Japan Relapsed Acute Myeloid Leukemia Drug Market Analysis
        5.5.1 Japan Relapsed Acute Myeloid Leukemia Drug Market Overview
        5.5.2 Japan 2013-2018E Relapsed Acute Myeloid Leukemia Drug Local Supply, Import, Export, Local Consumption Analysis
        5.5.3 Japan 2013-2018E Relapsed Acute Myeloid Leukemia Drug Sales Price Analysis
        5.5.4 Japan 2017 Relapsed Acute Myeloid Leukemia Drug Market Share Analysis
    5.6 India Relapsed Acute Myeloid Leukemia Drug Market Analysis
        5.6.1 India Relapsed Acute Myeloid Leukemia Drug Market Overview
        5.6.2 India 2013-2018E Relapsed Acute Myeloid Leukemia Drug Local Supply, Import, Export, Local Consumption Analysis
        5.6.3 India 2013-2018E Relapsed Acute Myeloid Leukemia Drug Sales Price Analysis
        5.6.4 India 2017 Relapsed Acute Myeloid Leukemia Drug Market Share Analysis

6 Global 2013-2018E Relapsed Acute Myeloid Leukemia Drug Segment Market Analysis (by Type)
    6.1 Global 2013-2018E Relapsed Acute Myeloid Leukemia Drug Sales by Type
    6.2 Different Types of Relapsed Acute Myeloid Leukemia Drug Product Interview Price Analysis
    6.3 Different Types of Relapsed Acute Myeloid Leukemia Drug Product Driving Factors Analysis
        6.3.1 aNK Program of Relapsed Acute Myeloid Leukemia Drug Growth Driving Factor Analysis
        6.3.2 AT-9283 of Relapsed Acute Myeloid Leukemia Drug Growth Driving Factor Analysis
        6.3.3 BI-836858 of Relapsed Acute Myeloid Leukemia Drug Growth Driving Factor Analysis
        6.3.4 binimetinib of Relapsed Acute Myeloid Leukemia Drug Growth Driving Factor Analysis
        6.3.5 BL-8040 of Relapsed Acute Myeloid Leukemia Drug Growth Driving Factor Analysis
        6.3.6 Others of Relapsed Acute Myeloid Leukemia Drug Growth Driving Factor Analysis

7 Global 2013-2018E Relapsed Acute Myeloid Leukemia Drug Segment Market Analysis (by Application)
    7.1 Global 2013-2018E Relapsed Acute Myeloid Leukemia Drug Consumption by Application
    7.2 Different Application of Relapsed Acute Myeloid Leukemia Drug Product Interview Price Analysis
    7.3 Different Application of Relapsed Acute Myeloid Leukemia Drug Product Driving Factors Analysis
        7.3.1 Clinic of Relapsed Acute Myeloid Leukemia Drug Growth Driving Factor Analysis
        7.3.2 Hospital of Relapsed Acute Myeloid Leukemia Drug Growth Driving Factor Analysis
        7.3.3 Others of Relapsed Acute Myeloid Leukemia Drug Growth Driving Factor Analysis

8 Major Manufacturers Analysis of Relapsed Acute Myeloid Leukemia Drug
    8.1 4SC AG
        8.1.1 Company Profile
        8.1.2 Product Picture and Specifications
            8.1.2.1 Product A
            8.1.2.2 Product B
        8.1.3 4SC AG 2017 Relapsed Acute Myeloid Leukemia Drug Sales, Ex-factory Price, Revenue, Gross Margin Analysis
        8.1.4 4SC AG 2017 Relapsed Acute Myeloid Leukemia Drug Business Region Distribution Analysis
    8.2 AbbVie Inc.
        8.2.1 Company Profile
        8.2.2 Product Picture and Specifications
            8.2.2.1 Product A
            8.2.2.2 Product B
        8.2.3 AbbVie Inc. 2017 Relapsed Acute Myeloid Leukemia Drug Sales, Ex-factory Price, Revenue, Gross Margin Analysis
        8.2.4 AbbVie Inc. 2017 Relapsed Acute Myeloid Leukemia Drug Business Region Distribution Analysis
    8.3 Actinium Pharmaceuticals, Inc.
        8.3.1 Company Profile
        8.3.2 Product Picture and Specifications
            8.3.2.1 Product A
            8.3.2.2 Product B
        8.3.3 Actinium Pharmaceuticals, Inc. 2017 Relapsed Acute Myeloid Leukemia Drug Sales, Ex-factory Price, Revenue, Gross Margin Analysis
        8.3.4 Actinium Pharmaceuticals, Inc. 2017 Relapsed Acute Myeloid Leukemia Drug Business Region Distribution Analysis
    8.4 Agios Pharmaceuticals, Inc.
        8.4.1 Company Profile
        8.4.2 Product Picture and Specifications
            8.4.2.1 Product A
            8.4.2.2 Product B
        8.4.3 Agios Pharmaceuticals, Inc. 2017 Relapsed Acute Myeloid Leukemia Drug Sales, Ex-factory Price, Revenue, Gross Margin Analysis
        8.4.4 Agios Pharmaceuticals, Inc. 2017 Relapsed Acute Myeloid Leukemia Drug Business Region Distribution Analysis
    8.5 Amgen Inc.
        8.5.1 Company Profile
        8.5.2 Product Picture and Specifications
            8.5.2.1 Product A
            8.5.2.2 Product B
        8.5.3 Amgen Inc. 2017 Relapsed Acute Myeloid Leukemia Drug Sales, Ex-factory Price, Revenue, Gross Margin Analysis
        8.5.4 Amgen Inc. 2017 Relapsed Acute Myeloid Leukemia Drug Business Region Distribution Analysis
    8.6 Arog Pharmaceuticals, Inc.
        8.6.1 Company Profile
        8.6.2 Product Picture and Specifications
            8.6.2.1 Product A
            8.6.2.2 Product B
        8.6.3 Arog Pharmaceuticals, Inc. 2017 Relapsed Acute Myeloid Leukemia Drug Sales, Ex-factory Price, Revenue, Gross Margin Analysis
        8.6.4 Arog Pharmaceuticals, Inc. 2017 Relapsed Acute Myeloid Leukemia Drug Business Region Distribution Analysis
    8.7 Array BioPharma Inc.
        8.7.1 Company Profile
        8.7.2 Product Picture and Specifications
            8.7.2.1 Product A
            8.7.2.2 Product B
        8.7.3 Array BioPharma Inc. 2017 Relapsed Acute Myeloid Leukemia Drug Sales, Ex-factory Price, Revenue, Gross Margin Analysis
        8.7.4 Array BioPharma Inc. 2017 Relapsed Acute Myeloid Leukemia Drug Business Region Distribution Analysis
    8.8 Astellas Pharma Inc.
        8.8.1 Company Profile
        8.8.2 Product Picture and Specifications
            8.8.2.1 Product A
            8.8.2.2 Product B
        8.8.3 Astellas Pharma Inc. 2017 Relapsed Acute Myeloid Leukemia Drug Sales, Ex-factory Price, Revenue, Gross Margin Analysis
        8.8.4 Astellas Pharma Inc. 2017 Relapsed Acute Myeloid Leukemia Drug Business Region Distribution Analysis
    8.9 Astex Pharmaceuticals, Inc.
        8.9.1 Company Profile
        8.9.2 Product Picture and Specifications
            8.9.2.1 Product A
            8.9.2.2 Product B
        8.9.3 Astex Pharmaceuticals, Inc. 2017 Relapsed Acute Myeloid Leukemia Drug Sales, Ex-factory Price, Revenue, Gross Margin Analysis
        8.9.4 Astex Pharmaceuticals, Inc. 2017 Relapsed Acute Myeloid Leukemia Drug Business Region Distribution Analysis
    8.10 AstraZeneca Plc
        8.10.1 Company Profile
        8.10.2 Product Picture and Specifications
            8.10.2.1 Product A
            8.10.2.2 Product B
        8.10.3 AstraZeneca Plc 2017 Relapsed Acute Myeloid Leukemia Drug Sales, Ex-factory Price, Revenue, Gross Margin Analysis
        8.10.4 AstraZeneca Plc 2017 Relapsed Acute Myeloid Leukemia Drug Business Region Distribution Analysis
    8.11 AVEO Pharmaceuticals, Inc.
    8.12 BioLineRx, Ltd.
    8.13 Boehringer Ingelheim GmbH
    8.14 Boston Biomedical, Inc.
    8.15 Bristol-Myers Squibb Company
    8.16 Calithera Biosciences, Inc.
    8.17 Celgene Corporation
    8.18 Cornerstone Pharmaceuticals, Inc.
    8.19 CTI BioPharma Corp.

9 Development Trend of Analysis of Relapsed Acute Myeloid Leukemia Drug Market
    9.1 Global Relapsed Acute Myeloid Leukemia Drug Market Trend Analysis
        9.1.1 Global 2018-2025 Relapsed Acute Myeloid Leukemia Drug Market Size (Volume and Value) Forecast
        9.1.2 Global 2018-2025 Relapsed Acute Myeloid Leukemia Drug Sales Price Forecast
    9.2 Relapsed Acute Myeloid Leukemia Drug Regional Market Trend
        9.2.1 North America 2018-2025 Relapsed Acute Myeloid Leukemia Drug Consumption Forecast
        9.2.2 China 2018-2025 Relapsed Acute Myeloid Leukemia Drug Consumption Forecast
        9.2.3 Europe 2018-2025 Relapsed Acute Myeloid Leukemia Drug Consumption Forecast
        9.2.4 Southeast Asia 2018-2025 Relapsed Acute Myeloid Leukemia Drug Consumption Forecast
        9.2.5 Japan 2018-2025 Relapsed Acute Myeloid Leukemia Drug Consumption Forecast
        9.2.6 India 2018-2025 Relapsed Acute Myeloid Leukemia Drug Consumption Forecast
    9.3 Relapsed Acute Myeloid Leukemia Drug Market Trend (Product Type)
    9.4 Relapsed Acute Myeloid Leukemia Drug Market Trend (Application)

10 Relapsed Acute Myeloid Leukemia Drug Marketing Type Analysis
    10.1 Relapsed Acute Myeloid Leukemia Drug Regional Marketing Type Analysis
    10.2 Relapsed Acute Myeloid Leukemia Drug International Trade Type Analysis
    10.3 Traders or Distributors with Contact Information of Relapsed Acute Myeloid Leukemia Drug by Region
    10.4 Relapsed Acute Myeloid Leukemia Drug Supply Chain Analysis

11 Consumers Analysis of Relapsed Acute Myeloid Leukemia Drug
    11.1 Consumer 1 Analysis
    11.2 Consumer 2 Analysis
    11.3 Consumer 3 Analysis
    11.4 Consumer 4 Analysis

12 Conclusion of the Global Relapsed Acute Myeloid Leukemia Drug Market Professional Survey Report 2017
    Methodology
    Analyst Introduction
    Data Source


List of Tables and Figures
    Figure Picture of Relapsed Acute Myeloid Leukemia Drug
    Table Product Specifications of Relapsed Acute Myeloid Leukemia Drug
    Table Classification of Relapsed Acute Myeloid Leukemia Drug
    Figure Global Production Market Share of Relapsed Acute Myeloid Leukemia Drug by Type in 2017
    Figure aNK Program Picture
    Table Major Manufacturers of aNK Program
    Figure AT-9283 Picture
    Table Major Manufacturers of AT-9283
    Figure BI-836858 Picture
    Table Major Manufacturers of BI-836858
    Figure binimetinib Picture
    Table Major Manufacturers of binimetinib
    Figure BL-8040 Picture
    Table Major Manufacturers of BL-8040
    Figure Others Picture
    Table Major Manufacturers of Others
    Table Applications of Relapsed Acute Myeloid Leukemia Drug
    Figure Global Consumption Volume Market Share of Relapsed Acute Myeloid Leukemia Drug by Application in 2017
    Figure Clinic Examples
    Table Major Consumers in Clinic
    Figure Hospital Examples
    Table Major Consumers in Hospital
    Figure Others Examples
    Table Major Consumers in Others
    Figure Market Share of Relapsed Acute Myeloid Leukemia Drug by Regions
    Figure North America Relapsed Acute Myeloid Leukemia Drug Market Size (Million USD) (2013-2025)
    Figure China Relapsed Acute Myeloid Leukemia Drug Market Size (Million USD) (2013-2025)
    Figure Europe Relapsed Acute Myeloid Leukemia Drug Market Size (Million USD) (2013-2025)
    Figure Southeast Asia Relapsed Acute Myeloid Leukemia Drug Market Size (Million USD) (2013-2025)
    Figure Japan Relapsed Acute Myeloid Leukemia Drug Market Size (Million USD) (2013-2025)
    Figure India Relapsed Acute Myeloid Leukemia Drug Market Size (Million USD) (2013-2025)
    Table Relapsed Acute Myeloid Leukemia Drug Raw Material and Suppliers
    Table Manufacturing Cost Structure Analysis of Relapsed Acute Myeloid Leukemia Drug in 2017
    Figure Manufacturing Process Analysis of Relapsed Acute Myeloid Leukemia Drug
    Figure Industry Chain Structure of Relapsed Acute Myeloid Leukemia Drug
    Table Capacity and Commercial Production Date of Global Relapsed Acute Myeloid Leukemia Drug Major Manufacturers in 2017
    Table Manufacturing Plants Distribution of Global Relapsed Acute Myeloid Leukemia Drug Major Manufacturers in 2017
    Table R&D Status and Technology Source of Global Relapsed Acute Myeloid Leukemia Drug Major Manufacturers in 2017
    Table Raw Materials Sources Analysis of Global Relapsed Acute Myeloid Leukemia Drug Major Manufacturers in 2017
    Table Global Capacity, Sales , Price, Cost, Sales Revenue (M USD) and Gross Margin of Relapsed Acute Myeloid Leukemia Drug 2013-2018E
    Figure Global 2013-2018E Relapsed Acute Myeloid Leukemia Drug Market Size (Volume) and Growth Rate
    Figure Global 2013-2018E Relapsed Acute Myeloid Leukemia Drug Market Size (Value) and Growth Rate
    Table 2013-2018E Global Relapsed Acute Myeloid Leukemia Drug Capacity and Growth Rate
    Table 2017 Global Relapsed Acute Myeloid Leukemia Drug Capacity (K Pcs) List (Company Segment)
    Table 2013-2018E Global Relapsed Acute Myeloid Leukemia Drug Sales (K Pcs) and Growth Rate
    Table 2017 Global Relapsed Acute Myeloid Leukemia Drug Sales (K Pcs) List (Company Segment)
    Table 2013-2018E Global Relapsed Acute Myeloid Leukemia Drug Sales Price (USD/Pcs)
    Table 2017 Global Relapsed Acute Myeloid Leukemia Drug Sales Price (USD/Pcs) List (Company Segment)
    Figure North America Capacity Overview
    Table North America Supply, Import, Export and Consumption (K Pcs) of Relapsed Acute Myeloid Leukemia Drug 2013-2018E 
    Figure North America 2013-2018E Relapsed Acute Myeloid Leukemia Drug Sales Price (USD/Pcs)
    Figure North America 2017 Relapsed Acute Myeloid Leukemia Drug Sales Market Share
    Figure China Capacity Overview
    Table China Supply, Import, Export and Consumption (K Pcs) of Relapsed Acute Myeloid Leukemia Drug 2013-2018E 
    Figure China 2013-2018E Relapsed Acute Myeloid Leukemia Drug Sales Price (USD/Pcs) 
    Figure China 2017 Relapsed Acute Myeloid Leukemia Drug Sales Market Share
    Figure Europe Capacity Overview
    Table Europe Supply, Import, Export and Consumption (K Pcs) of Relapsed Acute Myeloid Leukemia Drug 2013-2018E
    Figure Europe 2013-2018E Relapsed Acute Myeloid Leukemia Drug Sales Price (USD/Pcs)
    Figure Europe 2017 Relapsed Acute Myeloid Leukemia Drug Sales Market Share
    Figure Southeast Asia Capacity Overview
    Table Southeast Asia Supply, Import, Export and Consumption (K Pcs) of Relapsed Acute Myeloid Leukemia Drug 2013-2018E
    Figure Southeast Asia 2013-2018E Relapsed Acute Myeloid Leukemia Drug Sales Price (USD/Pcs)
    Figure Southeast Asia 2017 Relapsed Acute Myeloid Leukemia Drug Sales Market Share
    Figure Japan Capacity Overview
    Table Japan Supply, Import, Export and Consumption (K Pcs) of Relapsed Acute Myeloid Leukemia Drug 2013-2018E
    Figure Japan 2013-2018E Relapsed Acute Myeloid Leukemia Drug Sales Price (USD/Pcs)
    Figure Japan 2017 Relapsed Acute Myeloid Leukemia Drug Sales Market Share
    Figure India Capacity Overview
    Table India Supply, Import, Export and Consumption (K Pcs) of Relapsed Acute Myeloid Leukemia Drug 2013-2018E
    Figure India 2013-2018E Relapsed Acute Myeloid Leukemia Drug Sales Price (USD/Pcs)
    Figure India 2017 Relapsed Acute Myeloid Leukemia Drug Sales Market Share
    Table Global 2013-2018E Relapsed Acute Myeloid Leukemia Drug Sales (K Pcs) by Type
    Table Different Types Relapsed Acute Myeloid Leukemia Drug Product Interview Price
    Table Global 2013-2018E Relapsed Acute Myeloid Leukemia Drug Sales (K Pcs) by Application
    Table Different Application Relapsed Acute Myeloid Leukemia Drug Product Interview Price
    Table 4SC AG Information List
    Table Product A Overview
    Table Product B Overview
    Table 2017 4SC AG Relapsed Acute Myeloid Leukemia Drug Revenue (Million USD), Sales (K Pcs), Ex-factory Price (USD/Pcs)
    Figure 2017 4SC AG Relapsed Acute Myeloid Leukemia Drug Business Region Distribution
    Table AbbVie Inc. Information List
    Table Product A Overview
    Table Product B Overview
    Table 2017 AbbVie Inc. Relapsed Acute Myeloid Leukemia Drug Revenue (Million USD), Sales (K Pcs), Ex-factory Price (USD/Pcs)
    Figure 2017 AbbVie Inc. Relapsed Acute Myeloid Leukemia Drug Business Region Distribution
    Table Actinium Pharmaceuticals, Inc. Information List
    Table Product A Overview
    Table Product B Overview
    Table 2015 Actinium Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Revenue (Million USD), Sales (K Pcs), Ex-factory Price (USD/Pcs)
    Figure 2017 Actinium Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Business Region Distribution
    Table Agios Pharmaceuticals, Inc. Information List
    Table Product A Overview
    Table Product B Overview
    Table 2017 Agios Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Revenue (Million USD), Sales (K Pcs), Ex-factory Price (USD/Pcs)
    Figure 2017 Agios Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Business Region Distribution
    Table Amgen Inc. Information List
    Table Product A Overview
    Table Product B Overview
    Table 2017 Amgen Inc. Relapsed Acute Myeloid Leukemia Drug Revenue (Million USD), Sales (K Pcs), Ex-factory Price (USD/Pcs)
    Figure 2017 Amgen Inc. Relapsed Acute Myeloid Leukemia Drug Business Region Distribution
    Table Arog Pharmaceuticals, Inc. Information List
    Table Product A Overview
    Table Product B Overview
    Table 2017 Arog Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Revenue (Million USD), Sales (K Pcs), Ex-factory Price (USD/Pcs)
    Figure 2017 Arog Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Business Region Distribution
    Table Array BioPharma Inc. Information List
    Table Product A Overview
    Table Product B Overview
    Table 2017 Array BioPharma Inc. Relapsed Acute Myeloid Leukemia Drug Revenue (Million USD), Sales (K Pcs), Ex-factory Price (USD/Pcs)
    Figure 2017 Array BioPharma Inc. Relapsed Acute Myeloid Leukemia Drug Business Region Distribution
    Table Astellas Pharma Inc. Information List
    Table Product A Overview
    Table Product B Overview
    Table 2017 Astellas Pharma Inc. Relapsed Acute Myeloid Leukemia Drug Revenue (Million USD), Sales (K Pcs), Ex-factory Price (USD/Pcs)
    Figure 2017 Astellas Pharma Inc. Relapsed Acute Myeloid Leukemia Drug Business Region Distribution
    Table Astex Pharmaceuticals, Inc. Information List
    Table Product A Overview
    Table Product B Overview
    Table 2017 Astex Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Revenue (Million USD), Sales (K Pcs), Ex-factory Price (USD/Pcs)
    Figure 2017 Astex Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Business Region Distribution
    Table AstraZeneca Plc Information List
    Table Product A Overview
    Table Product B Overview
    Table 2017 AstraZeneca Plc Relapsed Acute Myeloid Leukemia Drug Revenue (Million USD), Sales (K Pcs), Ex-factory Price (USD/Pcs)
    Figure 2017 AstraZeneca Plc Relapsed Acute Myeloid Leukemia Drug Business Region Distribution
    Table AVEO Pharmaceuticals, Inc. Information List
    Table BioLineRx, Ltd. Information List
    Table Boehringer Ingelheim GmbH Information List
    Table Boston Biomedical, Inc. Information List
    Table Bristol-Myers Squibb Company Information List
    Table Calithera Biosciences, Inc. Information List
    Table Celgene Corporation Information List
    Table Cornerstone Pharmaceuticals, Inc. Information List
    Table CTI BioPharma Corp. Information List
    Figure Global 2018-2025 Relapsed Acute Myeloid Leukemia Drug Market Size (K Pcs) and Growth Rate Forecast
    Figure Global 2018-2025 Relapsed Acute Myeloid Leukemia Drug Market Size (Million USD) and Growth Rate Forecast
    Figure Global 2018-2025 Relapsed Acute Myeloid Leukemia Drug Sales Price (USD/Pcs) Forecast
    Figure North America 2018-2025 Relapsed Acute Myeloid Leukemia Drug Consumption Volume (K Pcs) and Growth Rate Forecast
    Figure China 2018-2025 Relapsed Acute Myeloid Leukemia Drug Consumption Volume (K Pcs) and Growth Rate Forecast
    Figure Europe 2018-2025 Relapsed Acute Myeloid Leukemia Drug Consumption Volume (K Pcs) and Growth Rate Forecast
    Figure Southeast Asia 2018-2025 Relapsed Acute Myeloid Leukemia Drug Consumption Volume (K Pcs) and Growth Rate Forecast
    Figure Japan 2018-2025 Relapsed Acute Myeloid Leukemia Drug Consumption Volume (K Pcs) and Growth Rate Forecast
    Figure India 2018-2025 Relapsed Acute Myeloid Leukemia Drug Consumption Volume (K Pcs) and Growth Rate Forecast
    Table Global Sales Volume (K Pcs) of Relapsed Acute Myeloid Leukemia Drug by Type 2018-2025
    Table Global Consumption Volume (K Pcs) of Relapsed Acute Myeloid Leukemia Drug by Application 2018-2025
    Table Traders or Distributors with Contact Information of Relapsed Acute Myeloid Leukemia Drug by Region